©The Author(s) 2022.
World J Hepatol. Aug 27, 2022; 14(8): 1562-1575
Published online Aug 27, 2022. doi: 10.4254/wjh.v14.i8.1562
Published online Aug 27, 2022. doi: 10.4254/wjh.v14.i8.1562
Table 1 Descriptive data of the studied hepatocellular carcinoma patients
| HCC | |||
| N = 70 | |||
| Demographic data | Age (yr) | 62.0 ± 7.6 | |
| Gender (%) | Female | 22 (31.4) | |
| Male | 48 (68.6) | ||
| Smoker (%) | No | 56 (80.0) | |
| Yes | 14 (20.0) | ||
| DM | No | 52 (74.3) | |
| (%) | Yes | 18 (25.7) | |
| BMI (kg/m2) | 27.7 (23.6- 31.9) | ||
| Laboratory investigation | Hb (g/dL) | 13.2 ± 1.9 | |
| WBC (× 103/µL) | 6.0 (4.6-8.0) | ||
| Platelets (× 103/µL) | 169.5 ± 77.9 | ||
| ALT (U/mL) | 52.5 (32.0- 74.3) | ||
| AST (U/mL) | 60.5 (38.0- 83.3) | ||
| Alb (g/dL) | 3.7 ± 0.5 | ||
| Bil.T (mg/dL) | 0.9 (0.6- 1.4) | ||
| AFP (ng/dL) | 38.8 (10.0- 370.0) | ||
| Creatinine (mg/dL) | 0.9 ± 0.2 | ||
| BCLC (%) | Early | 34 (48.6) | |
| Intermediate | 23 (32.9) | ||
| Late | 13 (18.6) | ||
| Performance status (%) | 0 | 43 (61.4) | |
| 1 | 24 (34.3) | ||
| 2 | 2 (2.9) | ||
| 3 | 1 (1.4) | ||
| Child grade (%) | A | 58 (82.9) | |
| B | 11 (15.7) | ||
| C | 1 (1.4) | ||
| Child score | 5.8 ± 1.0 | ||
| Number of HCCs (%) | Single | 49 (70.0) | |
| Two | 12 (17.1) | ||
| ≥ 3 | 9 (12.9) | ||
| Site of HCC (%) | Right lobe | 59 (84.3) | |
| Left lobe | 7 (10.0) | ||
| Both lobes | 4 (5.7) | ||
| HCC size (cm) | 4.0 (2.7- 5.0) | ||
| Portal vein | Patent | 65 (92.9) | |
| (%) | |||
| Thrombosed | 5 (7.1) | ||
| Abdominal lymphadenopathy | No | 65 (92.9) | |
| (%) | Yes | 5 (7.1) | |
| Decision of treatment | Best supportive care | 7 (10.0) | |
| Combined therapy | 1 (1.4) | ||
| (%) | Hepatectomy | 3 (4.3) | |
| Microwave ablation | 20 (28.5) | ||
| Radioembolization | 3 (4.3) | ||
| Sorafinib | 3 (4.3) | ||
| TACE | 29 (41.4) | ||
| Response to treatment according to mRECIST (%) | Stationary | 4 (7.8) | |
| Partial response | 7 (13.7) | ||
| Complete response | 34 (66.7) | ||
| Progressive disease | 6 (11.8) | ||
| Clinical decompensation (%) | Yes | 9 (12.9) | |
| No | 61 (54.5) | ||
| Alive or dead (%) | Dead | 34 (48.6) | |
| Alive | 36 (51.4) | ||
| Survival (days) | 367.1 ± 173.9 | ||
| miRNA-326 | 35.0 (12.5- 162.3) | ||
| miRNA-511 | 1.2 (0.3- 3.2) | ||
| miRNA-424 | 5.1 (2.9- 10.3) | ||
- Citation: Youssef SS, Elfiky A, Nabeel MM, Shousha HI, Elbaz T, Omran D, Marie MS, Elzahry MA, Abul-Fotouh A, Hashem A, Guda MF, Abdelaziz AO. Assessment of circulating levels of microRNA-326, microRNA-424, and microRNA-511 as biomarkers for hepatocellular carcinoma in Egyptians. World J Hepatol 2022; 14(8): 1562-1575
- URL: https://www.wjgnet.com/1948-5182/full/v14/i8/1562.htm
- DOI: https://dx.doi.org/10.4254/wjh.v14.i8.1562